SCHEMBL3559969

SCHEMBL3559969

CN(C)CCOc1c(-c2ccccc2)n(S(=O)(=O)c2ccccc2)c2c(Br)cc(Br)cc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 10/20 0.37
HTR7 P34969 5/20 0.36
KDM4E B2RXH2 3/20 0.35
ALDH1A1 P00352 3/20 0.35
LMNA P02545 1/20 0.35
HTR1A P08908 3/20 0.35
DRD2 P14416 3/20 0.35
HTR1D P28221 3/20 0.35
HTR1B P28222 3/20 0.35
HTR1F P30939 3/20 0.35
DRD3 P35462 3/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
TACR3 P29371 2/20 0.34
SIGMAR1 Q99720 2/20 0.34
HTR1E P28566 1/20 0.34
KCNH2 Q12809 1/20 0.34
MEN1 O00255 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3562280 0.96 CHRM2 (0.36) HTR6HTR7KDM4EALDH1A1LMNA
SCHEMBL3555633 0.94 AGTR1 (0.39) HTR6HTR7KDM4EALDH1A1LMNA
SCHEMBL3555923 0.93 HTR6 (0.43) HTR6HTR7KDM4EALDH1A1LMNA
SCHEMBL3563419 0.93 HTR6 (0.37) HTR6KDM4EALDH1A1LMNASMN1; SMN2
SCHEMBL3564860 0.92 HTR6 (0.37) HTR6HTR7KDM4EALDH1A1LMNA
SCHEMBL3567877 0.90 HTR7 (0.37) HTR6HTR7KDM4EALDH1A1LMNA
SCHEMBL3558834 0.90 HTR6 (0.36) HTR6HTR7KDM4EALDH1A1HTR1A
SCHEMBL3556559 0.88 HTR6 (0.45) HTR6HTR7KDM4EALDH1A1LMNA
SCHEMBL3556312 0.88 KDM4E (0.36) HTR6HTR7KDM4EALDH1A1LMNA
SCHEMBL3935893 0.87 ACLY (0.35) HTR7KDM4EALDH1A1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1567492-B1 N-ARYLSULFONYL-3-AMINOALKOXYINDOLES SUVEN LIFE SCIENCES LTD (IN) 2013-05-22 EP claimed
US-7507835-B2 N-arylsulfonyl-3-aminoalkoxyindoles SUVEN LIFE SCIENCES LTD. (IN) 2009-03-24 US claimed
US-20060173193-A1 N-arylsulfonyl-3-aminoalkoxyindoles SUVEN LIFE SCIENCES LIMITED (IN) 2006-08-03 US claimed
EP-1567492-A2 N-ARYLSULFONYL-3-AMINOALKOXYINDOLES Suven Life Sciences Limited (IN) 2005-08-31 EP claimed
WO-2004048328-A2 N-ARYLSULFONYL-3-AMINOALKOXYINDOLES SUVEN LIFE SCIENCES LIMITED (IN) 2004-06-10 WO claimed
EP-1567492-B1 N-ARYLSULFONYL-3-AMINOALKOXYINDOLES SUVEN LIFE SCIENCES LTD (IN) 2013-05-22 EP disclosed
US-7718690-B2 N-arylsulfonyl-3-aminoalkoxyindoles RAMAKRISHNA VENKATA SATYA NIROGI 2010-05-18 US disclosed
US-20090131507-A1 N-arylsulfonyl-3-aminoalkoxyindoles SUVEN LIFE SCIENCES LIMITED (IN) 2009-05-21 US disclosed
US-7507835-B2 N-arylsulfonyl-3-aminoalkoxyindoles SUVEN LIFE SCIENCES LTD. (IN) 2009-03-24 US disclosed
US-20060173193-A1 N-arylsulfonyl-3-aminoalkoxyindoles SUVEN LIFE SCIENCES LIMITED (IN) 2006-08-03 US disclosed
EP-1567492-A2 N-ARYLSULFONYL-3-AMINOALKOXYINDOLES Suven Life Sciences Limited (IN) 2005-08-31 EP disclosed
WO-2004048328-A2 N-ARYLSULFONYL-3-AMINOALKOXYINDOLES SUVEN LIFE SCIENCES LIMITED (IN) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131507-A1 N-arylsulfonyl-3-aminoalkoxyindoles HTR3C, HTR3A, AANAT HTR6 56/4885HTR7 51/4885KDM4E 3751/4885
US-20060173193-A1 N-arylsulfonyl-3-aminoalkoxyindoles HTR3C, HTR3A, AANAT HTR6 56/4885HTR7 51/4885KDM4E 3751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.